

Characterization of intact Parathyroid hormone and its fragments by Liquid Chromatography coupled to High-Resolution Mass Spectrometry

Massonnet P.(1), Henri L-H (1), Farré Segura J.(1,2), Peeters S.(1), Grifnée E.(1), Demeuse J.(1,2), Huyghebaert L.(1), Dubrowski T.(1), Schoumacher M.(1)
Le Goff C.(1,2), Cavalier E.(1,2)

¹ Department of Clinical Chemistry, University of Liège, CHU Sart-Tilman, B-4000 Liège, Belgium.

² Center for Interdisciplinary Research on Medicines (CIRM), ULiège, Belgium

Email: pmassonnet@chuliege.be

Introduction

- Parathyroid hormone (PTH) is a 84 amino acids peptide synthesized by the parathyroid glands (PTGs). Intact PTH (PTH 1-84) plays an important role in the calcium phosphate metabolism (1).
- PTH 1-84 is routinely quantified for the diagnosis of primary and secondary hyperparathyroidism (2).
- In addition to PTH 1-84, various fragments can be detected in plasma samples and can represent up to 80% of circulating PTH.
- The exact role of these fragments is still unclear but these species are known to be high in abundance in the case of chronic kidney disease (CKD) (3).
- The goal of this study is to develop a LC-MS method using high resolution mass spectrometry (HRMS).

LC-HRMS development

- Figure 1 depicts the extracted chromatograms for all species from table 1.
- In all cases, most abundant charge state is considered.




Figure 1: Chromatograms of all PTH species represented in table 1. Data were obtained in full scan.

- PTH 1-84 is clearly separated from all other peaks.
- Separation could be improved between PTH 37-77 and PTH 37-84.

TOF-MRM development

Table 2: TOF-MRM parameters developed in this study

Species	Parent ion (m/z)	Daughter ion (m/z)	Fragment identity	Collision Energy
PTH 1-84	725,56	770,43	$Y_{82}^{[12+]}$	20 V
PTH 28-84	618,60	671,61	$Y_{25}^{[4+]}$	19 V
PTH 34-77	674,18	745,37	$Y_{42}^{[6+]}$	17 V
PTH 34-84	684,59	747,08	$Y_{49}^{[7+]}$	19 V
PTH 37-77	628,88	714,02	$b_{40}^{[6+]}$	17 V
PTH 37-84	644,94	702,50	$Y_{45}^{[7+]}$	20 V
PTH 38-77	714,68	834,00	$b_{39}^{[5+]}$	24 V
PTH 38-84	630,81	688,60	$Y_{44}^{[7+]}$	22 V
PTH 45-84	730,35	992,82	$b_{27}^{[3+]}$	28 V




Figure 2: PTH 38-77 calibration curve (without immunocapture) obtained using TOF-MRM detection.

- Concentrations of about 5ng/mL (depending on the peptide) were successfully detected using TOF-MRM mode.

Immunocapture results

Table 3: Fixation % of all species depending on the considered antibody

Species	% of sample		Concentration (ng/mL)
	fixed on N-term Ab	fixed on C-term Ab	
PTH 1-84	22,2	49,4	8,77
PTH 28-84	47,3	78,0	7,02
PTH 34-77	43,2	40,3	7,02
PTH 34-84	39,2	40,9	6,93
PTH 37-77	17,5	41,2	6,93
PTH 37-84	16,4	26,4	6,84
PTH 38-77	29,0	21,6	6,84
PTH 38-84	89,1	89,2	6,84
PTH 45-84	62,0	12,4	6,75

- Overall, C-term Ab provides higher fixation yield.
- PTH 38-84 seems the most fixed species while PTH 38-77 gives low results.

Conclusions and prospects

- One LC-HRMS method has been developed for the separation and the quantitation of 9 PTH species.
- Values around 5ng/mL can be detected with and without sample preparation.
- First immunocapture tests show globally better results with the C-term Ab.
- Labelled internal standard will be use to normalize results.
- Combination of TOF-MRM and full-scan mode could be usefull in the future.

Material and methods

1) Peptides

Table 1: List of peptides used in this study

Species	Amino acid sequence	Monoisotopic non protonated mass (Da)
PTH 1-84	SVSEIQLMHNHLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQR PRKKEDNVLVESHEKSLGEADKADVNVLTAKKSQ	9418,96
PTH 28-84	LQDVHNFVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTAKKSQ	6175,25
PTH 34-77	FVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNV	4712,46
PTH 34-84	FVALGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTAKKSQ	5468,91
PTH 37-77	LGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNV	4395,29
PTH 37-84	LGAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTAKKSQ	5151,74
PTH 38-77	GAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNV	4282,21
PTH 38-84	GAPLAPRDAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTAKKSQ	5038,65
PTH 45-84	DAGSQRPRKKEDNVLVESHEKSLGEADKADVNVLTAKKSQ	4376,27

2) LC-MS conditions

- LC-MS experiments were performed using a SYNAPT XS mass spectrometer in positive ion mode coupled with a NanoAcquity UPLC system equipped with a Protein BEH C4 column (300Å, 1.7µm, 300µmx100 mm of Waters corporation). Acquisition was performed in full scan and TOF-MRM modes.

Gradient conditions:	Time (min.)	%B
*Flow: 15µL/min	0	5
* Injection volume: 5 µL	1	5
* Mobile phases:	12,5	60
A: H ₂ O; 0.4% HCOOH; 5% DMSO	13	95
B: Acetonitrile; 0.4% HCOOH; 5% DMSO	14	95
	15	5
	16	95
	20	5

3) Immunocapture protocol

- On-beads Immunocapture protocol:

 1. 0.5 mg beads (Biorad, SureBeads, Protein G) washes: 2x PBS and 1x PBS-Tween.
 2. Antibody coupling (PTH N-term and PTH C-term from Abcam company): + 150µL (6.7µg/mL), incubation (10 min., 1200rpm, 25°C) followed by the 3 washing steps (same as above).
 3. Sample incubation: +150µL at 5ng/mL sample ; 1x PBS wash and 1 NaHCO₃ 50mM washes and 1h incubation (1h; 1200rpm; 25°C).
 4. Elution: +200µL (50% ACN; 0.1%FA) followed by 5 minutes incubation (1600rpm; 25°C).
 5. Evaporation and reconstitution in 50µL of 10% ACN; 0.1%FA.

Acknowledgments

The authors thank the «Fonds d'Investissement de la Recherche Scientifique» (FIRS) of CHU of Liège for the financial support.

Bibliography

- 1) Massart C. et al. Immuno-analyse & Biologie Spécialisée; 2012;27(2):79-82.
- 2) Farré-Segura J. et al. Clinical Chemistry; 2022; 38(11):1399-1409.
- 3) Kritmetapak K. et al. Clinical Chemistry; 2021; 67(6):843-53.